Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine
Sleep propensity at daytime has not been investigated in untreated patients with schizophrenia. Furthermore, while the antipsychotics clozapine and olanzapine are considered to frequently cause ‘sleepiness’ or ‘sedation’, this has not been objectified yet. Therefore, 30 patients with schizophrenia w...
Saved in:
| Published in | Schizophrenia research Vol. 135; no. 1-3; pp. 123 - 127 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Amsterdam
Elsevier B.V
01.03.2012
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0920-9964 1573-2509 1573-2509 |
| DOI | 10.1016/j.schres.2011.12.017 |
Cover
Loading…
| Abstract | Sleep propensity at daytime has not been investigated in untreated patients with schizophrenia. Furthermore, while the antipsychotics clozapine and olanzapine are considered to frequently cause ‘sleepiness’ or ‘sedation’, this has not been objectified yet. Therefore, 30 patients with schizophrenia were included in this randomized, double-blind study. Sleep propensity was assessed before and after 2, 4 and 6weeks of treatment with either clozapine or olanzapine using a Multiple Sleep Latency Test (MSLT); in the MSLT, sleep latencies of 5 nap opportunities of 20min during daytime are averaged. In addition, the number of sleep onsets was recorded. Mean sleep latency in untreated schizophrenic patients was 16.2±0.8min at baseline. Both antipsychotics induced an increase of sleep propensity as indicated by a shortened sleep latency and more sleep onsets during the treatment period as compared to baseline. These effects were strongest in the morning. Four patients receiving clozapine and 3 patients receiving olanzapine reported subjective sleepiness, in all but one commencing in the first treatment week and persisting until study end. While the mean sleep latency during treatment was significantly shorter in these patients (12.3±0.8min) than in those without subjective sleepiness (14.9±0.7min), a short sleep latency was not necessarily associated with subjective sleepiness.
In conclusion, mean sleep latency was >36% longer (i.e. sleep propensity was lower) in untreated patients with schizophrenia than in healthy subjects previously consistently reported. Furthermore, clozapine and olanzapine increased sleep propensity in schizophrenic patients. A minority of patients reported subjective sleepiness. |
|---|---|
| AbstractList | Sleep propensity at daytime has not been investigated in untreated patients with schizophrenia. Furthermore, while the antipsychotics clozapine and olanzapine are considered to frequently cause ‘sleepiness’ or ‘sedation’, this has not been objectified yet. Therefore, 30 patients with schizophrenia were included in this randomized, double-blind study. Sleep propensity was assessed before and after 2, 4 and 6weeks of treatment with either clozapine or olanzapine using a Multiple Sleep Latency Test (MSLT); in the MSLT, sleep latencies of 5 nap opportunities of 20min during daytime are averaged. In addition, the number of sleep onsets was recorded. Mean sleep latency in untreated schizophrenic patients was 16.2±0.8min at baseline. Both antipsychotics induced an increase of sleep propensity as indicated by a shortened sleep latency and more sleep onsets during the treatment period as compared to baseline. These effects were strongest in the morning. Four patients receiving clozapine and 3 patients receiving olanzapine reported subjective sleepiness, in all but one commencing in the first treatment week and persisting until study end. While the mean sleep latency during treatment was significantly shorter in these patients (12.3±0.8min) than in those without subjective sleepiness (14.9±0.7min), a short sleep latency was not necessarily associated with subjective sleepiness.
In conclusion, mean sleep latency was >36% longer (i.e. sleep propensity was lower) in untreated patients with schizophrenia than in healthy subjects previously consistently reported. Furthermore, clozapine and olanzapine increased sleep propensity in schizophrenic patients. A minority of patients reported subjective sleepiness. Sleep propensity at daytime has not been investigated in untreated patients with schizophrenia. Furthermore, while the antipsychotics clozapine and olanzapine are considered to frequently cause 'sleepiness' or 'sedation', this has not been objectified yet. Therefore, 30 patients with schizophrenia were included in this randomized, double-blind study. Sleep propensity was assessed before and after 2, 4 and 6 weeks of treatment with either clozapine or olanzapine using a Multiple Sleep Latency Test (MSLT); in the MSLT, sleep latencies of 5 nap opportunities of 20 min during daytime are averaged. In addition, the number of sleep onsets was recorded. Mean sleep latency in untreated schizophrenic patients was 16.2 ± 0.8 min at baseline. Both antipsychotics induced an increase of sleep propensity as indicated by a shortened sleep latency and more sleep onsets during the treatment period as compared to baseline. These effects were strongest in the morning. Four patients receiving clozapine and 3 patients receiving olanzapine reported subjective sleepiness, in all but one commencing in the first treatment week and persisting until study end. While the mean sleep latency during treatment was significantly shorter in these patients (12.3 ± 0.8 min) than in those without subjective sleepiness (14.9 ± 0.7 min), a short sleep latency was not necessarily associated with subjective sleepiness. In conclusion, mean sleep latency was >36% longer (i.e. sleep propensity was lower) in untreated patients with schizophrenia than in healthy subjects previously consistently reported. Furthermore, clozapine and olanzapine increased sleep propensity in schizophrenic patients. A minority of patients reported subjective sleepiness.Sleep propensity at daytime has not been investigated in untreated patients with schizophrenia. Furthermore, while the antipsychotics clozapine and olanzapine are considered to frequently cause 'sleepiness' or 'sedation', this has not been objectified yet. Therefore, 30 patients with schizophrenia were included in this randomized, double-blind study. Sleep propensity was assessed before and after 2, 4 and 6 weeks of treatment with either clozapine or olanzapine using a Multiple Sleep Latency Test (MSLT); in the MSLT, sleep latencies of 5 nap opportunities of 20 min during daytime are averaged. In addition, the number of sleep onsets was recorded. Mean sleep latency in untreated schizophrenic patients was 16.2 ± 0.8 min at baseline. Both antipsychotics induced an increase of sleep propensity as indicated by a shortened sleep latency and more sleep onsets during the treatment period as compared to baseline. These effects were strongest in the morning. Four patients receiving clozapine and 3 patients receiving olanzapine reported subjective sleepiness, in all but one commencing in the first treatment week and persisting until study end. While the mean sleep latency during treatment was significantly shorter in these patients (12.3 ± 0.8 min) than in those without subjective sleepiness (14.9 ± 0.7 min), a short sleep latency was not necessarily associated with subjective sleepiness. In conclusion, mean sleep latency was >36% longer (i.e. sleep propensity was lower) in untreated patients with schizophrenia than in healthy subjects previously consistently reported. Furthermore, clozapine and olanzapine increased sleep propensity in schizophrenic patients. A minority of patients reported subjective sleepiness. Sleep propensity at daytime has not been investigated in untreated patients with schizophrenia. Furthermore, while the antipsychotics clozapine and olanzapine are considered to frequently cause 'sleepiness' or 'sedation', this has not been objectified yet. Therefore, 30 patients with schizophrenia were included in this randomized, double-blind study. Sleep propensity was assessed before and after 2, 4 and 6 weeks of treatment with either clozapine or olanzapine using a Multiple Sleep Latency Test (MSLT); in the MSLT, sleep latencies of 5 nap opportunities of 20 min during daytime are averaged. In addition, the number of sleep onsets was recorded. Mean sleep latency in untreated schizophrenic patients was 16.2 ± 0.8 min at baseline. Both antipsychotics induced an increase of sleep propensity as indicated by a shortened sleep latency and more sleep onsets during the treatment period as compared to baseline. These effects were strongest in the morning. Four patients receiving clozapine and 3 patients receiving olanzapine reported subjective sleepiness, in all but one commencing in the first treatment week and persisting until study end. While the mean sleep latency during treatment was significantly shorter in these patients (12.3 ± 0.8 min) than in those without subjective sleepiness (14.9 ± 0.7 min), a short sleep latency was not necessarily associated with subjective sleepiness. In conclusion, mean sleep latency was >36% longer (i.e. sleep propensity was lower) in untreated patients with schizophrenia than in healthy subjects previously consistently reported. Furthermore, clozapine and olanzapine increased sleep propensity in schizophrenic patients. A minority of patients reported subjective sleepiness. Abstract Sleep propensity at daytime has not been investigated in untreated patients with schizophrenia. Furthermore, while the antipsychotics clozapine and olanzapine are considered to frequently cause ‘sleepiness’ or ‘sedation’, this has not been objectified yet. Therefore, 30 patients with schizophrenia were included in this randomized, double-blind study. Sleep propensity was assessed before and after 2, 4 and 6 weeks of treatment with either clozapine or olanzapine using a Multiple Sleep Latency Test (MSLT); in the MSLT, sleep latencies of 5 nap opportunities of 20 min during daytime are averaged. In addition, the number of sleep onsets was recorded. Mean sleep latency in untreated schizophrenic patients was 16.2 ± 0.8 min at baseline. Both antipsychotics induced an increase of sleep propensity as indicated by a shortened sleep latency and more sleep onsets during the treatment period as compared to baseline. These effects were strongest in the morning. Four patients receiving clozapine and 3 patients receiving olanzapine reported subjective sleepiness, in all but one commencing in the first treatment week and persisting until study end. While the mean sleep latency during treatment was significantly shorter in these patients (12.3 ± 0.8 min) than in those without subjective sleepiness (14.9 ± 0.7 min), a short sleep latency was not necessarily associated with subjective sleepiness. In conclusion, mean sleep latency was > 36% longer (i.e. sleep propensity was lower) in untreated patients with schizophrenia than in healthy subjects previously consistently reported. Furthermore, clozapine and olanzapine increased sleep propensity in schizophrenic patients. A minority of patients reported subjective sleepiness. |
| Author | Rummel-Kluge, Christine Wehmeier, Peter M. Kraus, Thomas Pollmächer, Thomas Dalal, Mira Dittmann, Ralf W. Kluge, Michael Hinze-Selch, Dunja Schuld, Andreas Himmerich, Hubertus |
| Author_xml | – sequence: 1 givenname: Michael surname: Kluge fullname: Kluge, Michael email: Michael.Kluge@medizin.uni-leipzig.de organization: Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany – sequence: 2 givenname: Hubertus surname: Himmerich fullname: Himmerich, Hubertus organization: Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany – sequence: 3 givenname: Peter M. surname: Wehmeier fullname: Wehmeier, Peter M. organization: Department of Child and Adolescent Psychiatry, Central Institute of Mental Health Mannheim, University of Heidelberg, Germany – sequence: 4 givenname: Christine surname: Rummel-Kluge fullname: Rummel-Kluge, Christine organization: Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany – sequence: 5 givenname: Mira surname: Dalal fullname: Dalal, Mira organization: Max Planck Institute of Psychiatry, Munich, Germany – sequence: 6 givenname: Dunja surname: Hinze-Selch fullname: Hinze-Selch, Dunja organization: Fachklinik St. Marienstift, Center for Psychiatric and Psychotherapeutic Treatment for Traumatized Males, Neuenkirchen, Germany – sequence: 7 givenname: Thomas surname: Kraus fullname: Kraus, Thomas organization: Frankenalb-Klinik, District Hospital of Psychiatry, Psychotherapy, Psychosomatics and Addiction Rehabilitation, Engelthal, Germany – sequence: 8 givenname: Ralf W. surname: Dittmann fullname: Dittmann, Ralf W. organization: Department of Child and Adolescent Psychiatry, Central Institute of Mental Health Mannheim, University of Heidelberg, Germany – sequence: 9 givenname: Thomas surname: Pollmächer fullname: Pollmächer, Thomas organization: Max Planck Institute of Psychiatry, Munich, Germany – sequence: 10 givenname: Andreas surname: Schuld fullname: Schuld, Andreas organization: Klinikum Ingolstadt, Center of Mental Health, Ingolstadt, Germany |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25564381$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22257975$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVUl2LEzEUHWTF_dB_IJIXUR9ak0wmaUQEWfyCLj60Poc0ucOmTjOzSarM_g__r7dMF0GQRQiE5J5z7se559VJ7CNU1VNG54wy-Xo7z-46QZ5zytic8Tll6kF1xhpVz3hD9Ul1RjWnM62lOK3Oc95SSllD1aPqlHPeKK2as-rXqgMYyJD6AWIOZSS2EG_HEnZAbMaTAY8nm5Fc7bsShg7IxFnaAtGNZA25ZPLyarVcvyIhksGWABG_foZyTbDIcNsPWGkMFsMugUXJKei6_tYOIWKq6Enf2Tg9H1cPW9tleHK8L6pvHz-sLz_Pll8_fbl8v5w5oXWZSRBStN5ZJ_yCK9W0VDpbayG5WmjVaqs3shVMsrZtvPC0ZdLX3FtLJZMLX19ULyZd7P9mj32YXcgOOiwE-n02mteNUpwJRD47IvebHXgzpLCzaTR3k0TA8yPAZme7NtnoQv6Daxop6gVD3JsJ51Kfc4LWuFBwYn0syYbOMGoO9pqtmew1B3sN4wbtRbL4i3ynfw_t3UQDnOWPAAlBaJEDHxK4Ynwf_lfAdSEG7PM7jJC3_T5F9Mkwk5FgVofFO-wdY5RKRSkKvP23wP35fwMnQew3 |
| CitedBy_id | crossref_primary_10_3389_fneur_2014_00264 crossref_primary_10_1016_j_jsmc_2018_02_001 crossref_primary_10_1371_journal_pone_0245301 crossref_primary_10_1080_14789949_2022_2111320 crossref_primary_10_1016_j_pharep_2014_07_007 crossref_primary_10_1016_j_jsmc_2022_06_011 crossref_primary_10_4161_15548627_2014_984274 crossref_primary_10_1186_s12888_016_0859_9 crossref_primary_10_1093_schbul_sbab124 crossref_primary_10_1016_j_cpr_2015_09_001 crossref_primary_10_1111_jsr_14360 crossref_primary_10_1016_j_schres_2013_11_009 crossref_primary_10_1002_14651858_CD008298_pub3 crossref_primary_10_1016_j_pnpbp_2012_12_021 |
| Cites_doi | 10.1176/appi.ajp.164.7.1050 10.1016/0006-3223(85)90167-2 10.1016/S0006-3223(96)00437-4 10.1046/j.1365-2869.2000.00177.x 10.1016/j.schres.2010.07.012 10.1378/chest.08-0822 10.1093/sleep/29.5.687 10.1093/brain/awl079 10.1093/sleep/28.1.123 10.1093/schbul/sbq043 10.1093/schbul/sbq042 10.1016/j.psychres.2007.06.001 10.1093/oxfordjournals.schbul.a007145 10.1176/appi.ajp.2008.08030368 10.1016/j.jpsychires.2011.05.009 10.1152/physrev.00043.2007 10.1016/j.schres.2004.01.008 10.1097/jcp.0b013e31815a8872 10.1007/s11065-005-6254-9 10.1093/schbul/21.4.579 10.1093/sleep/9.4.519 10.1016/j.schres.2009.05.024 10.1097/WNP.0b013e31811ec488 10.1016/0893-133X(94)00129-N 10.1016/j.psychres.2009.08.009 10.1016/j.psyneuen.2008.08.016 10.1093/sleep/29.7.890 10.1016/j.psychres.2006.04.003 10.1016/j.schres.2010.03.019 10.1016/j.clinph.2006.01.017 10.1046/j.1365-2869.1999.00168.x 10.1093/sleep/14.6.540 10.1055/s-2005-837764 10.1177/0269881105056657 |
| ContentType | Journal Article |
| Copyright | 2011 Elsevier B.V. Elsevier B.V. 2015 INIST-CNRS Copyright © 2011 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2011 Elsevier B.V. – notice: Elsevier B.V. – notice: 2015 INIST-CNRS – notice: Copyright © 2011 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.schres.2011.12.017 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1573-2509 |
| EndPage | 127 |
| ExternalDocumentID | 22257975 25564381 10_1016_j_schres_2011_12_017 S0920996411006700 1_s2_0_S0920996411006700 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- --K --M -~X .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 4H- 53G 5VS 7-5 71M 8P~ 9JM 9JO AABNK AADFP AAEDT AAEDW AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABIVO ABJNI ABMAC ABMZM ABOYX ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACIUM ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEG HMK HMO HMQ HMW HVGLF HZ~ IHE J1W KOM M29 M2V M39 M3V M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPS SSB SSH SSN SSY SSZ T5K WUQ Z5R ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AADPK AAIAV ABLVK ABYKQ AFYLN AJBFU LCYCR AAYXX AGRNS CITATION ABPIF ABPTK IQODW CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c499t-6e464fdcac4d82775f06ca394627897f9a9b6f4161ff5d4d0f16d32daa06168d3 |
| IEDL.DBID | .~1 |
| ISSN | 0920-9964 1573-2509 |
| IngestDate | Fri Jul 11 04:39:32 EDT 2025 Thu Apr 03 07:08:23 EDT 2025 Sun Oct 22 16:10:03 EDT 2023 Tue Jul 01 04:00:27 EDT 2025 Thu Apr 24 22:52:42 EDT 2025 Mon Apr 15 08:35:49 EDT 2024 Sun Feb 23 10:19:47 EST 2025 Tue Aug 26 18:10:54 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1-3 |
| Keywords | Schizophrenia Atypical antipsychotics Sedation Sleepiness Human Dibenzodiazepine derivatives Atypical antipsychotic Olanzapine Neuroleptic Psychotropic Dopamine antagonist Serotonin antagonist Asleeping Serotonine receptor Clozapine Waiting time Thienobenzodiazepine derivatives Psychosis Somnolence D2 Dopamine receptor Sleep Sleep wake cycle |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2011 Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c499t-6e464fdcac4d82775f06ca394627897f9a9b6f4161ff5d4d0f16d32daa06168d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 22257975 |
| PQID | 923577214 |
| PQPubID | 23479 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_923577214 pubmed_primary_22257975 pascalfrancis_primary_25564381 crossref_citationtrail_10_1016_j_schres_2011_12_017 crossref_primary_10_1016_j_schres_2011_12_017 elsevier_sciencedirect_doi_10_1016_j_schres_2011_12_017 elsevier_clinicalkeyesjournals_1_s2_0_S0920996411006700 elsevier_clinicalkey_doi_10_1016_j_schres_2011_12_017 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-03-01 |
| PublicationDateYYYYMMDD | 2012-03-01 |
| PublicationDate_xml | – month: 03 year: 2012 text: 2012-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Amsterdam |
| PublicationPlace_xml | – name: Amsterdam – name: Netherlands |
| PublicationTitle | Schizophrenia research |
| PublicationTitleAlternate | Schizophr Res |
| PublicationYear | 2012 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Kluge, Schuld, Himmerich, Dalal, Schacht, Wehmeier, Hinze-Selch, Kraus, Dittmann, Pollmächer (bb0085) 2007; 27 Nakagami, Hoe, Brekke (bb0130) 2010; 36 Wichniak, Szafranski, Wierzbicka, Waliniowska, Jernajczyk (bb0185) 2006; 20 Leucht, Komossa, Rummel-Kluge, Corves, Hunger, Schmid, Asenjo, Schwarz, Davis (bb0110) 2009; 166 Oken, Salinsky, Elsas (bb0135) 2006; 117 Dinzeo, Cohen, Nienow, Docherty (bb0045) 2004; 71 Singh, Drake, Roth (bb0170) 2006; 29 Betensky, Robinson, Gunduz-Bruce, Sevy, Lencz, Kane, Malhotra, Miller, McCormack, Bilder, Szeszko (bb0010) 2008; 160 Carter, Bizzell, Kim, Bellion, Carpenter, Dichter, Belger (bb0035) 2010; 122 Buchanan (bb0020) 1995; 21 Kluge, Schüssler, Dresler, Yassouridis, Steiger (bb0095) 2007; 152 Johns (bb0070) 2000; 9 Kluge, Schuld, Schacht, Himmerich, Dalal, Wehmeier, Hinze-Selch, Kraus, Dittmann, Pollmächer (bb0090) 2009; 34 Wichniak, Skowerska, Chojnacka-Wojtowicz, Taflinski, Wierzbicka, Jernajczyk, Jarema (bb0180) 2011; 45 Pollmächer, Mullington, Lauer (bb0140) 1997; 42 Fioravanti, Carlone, Vitale, Cinti, Clare (bb0050) 2005; 15 Arand, Bonnet, Hurwitz, Mitler, Rosa, Sangal (bb0005) 2005; 28 Rummel-Kluge, Komossa, Schwarz, Hunger, Schmid, Lobos, Kissling, Davis, Leucht (bb0160) 2010; 123 Rummel-Kluge, Komossa, Schwarz, Hunger, Schmid, Kissling, Davis, Leucht (bb0155) 2012; 38 Bonnet, Arand (bb0015) 1999; 8 Chouinard, Poulin, Stip, Godbout (bb0040) 2004; 30 Geisler, Tracik, Crönlein, Fulda, Wichniak, Popp, Zulley, Hajak (bb0055) 2006; 29 Kluge, Wehmeier, Dittmann, Langer, Czekalla, Lehmann, Kessler, Beyenburg, Naber (bb0100) 2005; 38 Mignot, Lin, Finn, Lopes, Pluff, Sundstrom, Young (bb0125) 2006; 129 Carskadon, Dement, Mitler, Roth, Westbrook, Keenan (bb0030) 1986; 9 Haas, Sergeeva, Selbach (bb0060) 2008; 88 Kumar, Greden, Grunhaus, Eiser (bb0105) 1985; 20 Poulin, Chouinard, Pampoulova, Lecomte, Stip, Godbout (bb0145) 2010; 179 Johns (bb0065) 1991; 14 Kasravi, Legault, Jewell, Murray (bb0080) 2007; 24 McEvoy, Lieberman, Perkins, Hamer, Gu, Lazarus, Sweitzer, Olexy, Weiden, Strakowski (bb0120) 2007; 164 Karagianis, Grossman, Landry, Reed, de, Maguire, Hoffmann, Milev (bb0075) 2009; 113 Bymaster, Calligaro, Falcone, Marsh, Moore, Tye, Seeman, Wong (bb0025) 1996; 14 Rechtschaffen, Kales (bb0150) 1968 Schulz, Lund (bb0165) 1983; 18 Mathis, Hess (bb0115) 2009; 139 Sullivan, Kushida (bb0175) 2008; 134 Kluge (10.1016/j.schres.2011.12.017_bb0090) 2009; 34 Kluge (10.1016/j.schres.2011.12.017_bb0095) 2007; 152 Rummel-Kluge (10.1016/j.schres.2011.12.017_bb0160) 2010; 123 Carskadon (10.1016/j.schres.2011.12.017_bb0030) 1986; 9 Wichniak (10.1016/j.schres.2011.12.017_bb0185) 2006; 20 Singh (10.1016/j.schres.2011.12.017_bb0170) 2006; 29 Kumar (10.1016/j.schres.2011.12.017_bb0105) 1985; 20 Fioravanti (10.1016/j.schres.2011.12.017_bb0050) 2005; 15 Pollmächer (10.1016/j.schres.2011.12.017_bb0140) 1997; 42 Rechtschaffen (10.1016/j.schres.2011.12.017_bb0150) 1968 Sullivan (10.1016/j.schres.2011.12.017_bb0175) 2008; 134 Nakagami (10.1016/j.schres.2011.12.017_bb0130) 2010; 36 Karagianis (10.1016/j.schres.2011.12.017_bb0075) 2009; 113 Geisler (10.1016/j.schres.2011.12.017_bb0055) 2006; 29 Haas (10.1016/j.schres.2011.12.017_bb0060) 2008; 88 Poulin (10.1016/j.schres.2011.12.017_bb0145) 2010; 179 Chouinard (10.1016/j.schres.2011.12.017_bb0040) 2004; 30 Dinzeo (10.1016/j.schres.2011.12.017_bb0045) 2004; 71 Johns (10.1016/j.schres.2011.12.017_bb0070) 2000; 9 Oken (10.1016/j.schres.2011.12.017_bb0135) 2006; 117 Kasravi (10.1016/j.schres.2011.12.017_bb0080) 2007; 24 Wichniak (10.1016/j.schres.2011.12.017_bb0180) 2011; 45 Schulz (10.1016/j.schres.2011.12.017_bb0165) 1983; 18 Kluge (10.1016/j.schres.2011.12.017_bb0100) 2005; 38 Kluge (10.1016/j.schres.2011.12.017_bb0085) 2007; 27 Johns (10.1016/j.schres.2011.12.017_bb0065) 1991; 14 Buchanan (10.1016/j.schres.2011.12.017_bb0020) 1995; 21 Rummel-Kluge (10.1016/j.schres.2011.12.017_bb0155) 2012; 38 Mignot (10.1016/j.schres.2011.12.017_bb0125) 2006; 129 Carter (10.1016/j.schres.2011.12.017_bb0035) 2010; 122 Bymaster (10.1016/j.schres.2011.12.017_bb0025) 1996; 14 Mathis (10.1016/j.schres.2011.12.017_bb0115) 2009; 139 Bonnet (10.1016/j.schres.2011.12.017_bb0015) 1999; 8 McEvoy (10.1016/j.schres.2011.12.017_bb0120) 2007; 164 Betensky (10.1016/j.schres.2011.12.017_bb0010) 2008; 160 Arand (10.1016/j.schres.2011.12.017_bb0005) 2005; 28 Leucht (10.1016/j.schres.2011.12.017_bb0110) 2009; 166 |
| References_xml | – volume: 14 start-page: 87 year: 1996 end-page: 96 ident: bb0025 article-title: Radioreceptor binding profile of the atypical antipsychotic olanzapine publication-title: Neuropsychopharmacology – volume: 14 start-page: 540 year: 1991 end-page: 545 ident: bb0065 article-title: A new method for measuring daytime sleepiness: the Epworth sleepiness scale publication-title: Sleep – volume: 129 start-page: 1609 year: 2006 end-page: 1623 ident: bb0125 article-title: Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults publication-title: Brain – volume: 21 start-page: 579 year: 1995 end-page: 591 ident: bb0020 article-title: Clozapine: efficacy and safety publication-title: Schizophr. Bull. – volume: 34 start-page: 118 year: 2009 end-page: 128 ident: bb0090 article-title: Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever publication-title: Psychoneuroendocrinology – volume: 18 start-page: 1411 year: 1983 end-page: 1426 ident: bb0165 article-title: Sleep onset REM episodes are associated with circadian parameters of body temperature. A study in depressed patients and normal controls publication-title: Biol. Psychiatry – volume: 179 start-page: 274 year: 2010 end-page: 278 ident: bb0145 article-title: Sleep habits in middle-aged, non-hospitalized men and women with schizophrenia: a comparison with healthy controls publication-title: Psychiatry Res. – volume: 27 start-page: 662 year: 2007 end-page: 666 ident: bb0085 article-title: Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study publication-title: J. Clin. Psychopharmacol. – volume: 9 start-page: 519 year: 1986 end-page: 524 ident: bb0030 article-title: Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness publication-title: Sleep – volume: 160 start-page: 38 year: 2008 end-page: 46 ident: bb0010 article-title: Patterns of stress in schizophrenia publication-title: Psychiatry Res. – volume: 38 start-page: 6 year: 2005 end-page: 12 ident: bb0100 article-title: A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being publication-title: Pharmacopsychiatry – volume: 9 start-page: 5 year: 2000 end-page: 11 ident: bb0070 article-title: Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the epworth sleepiness scale: failure of the MSLT as a gold standard publication-title: J. Sleep Res. – volume: 122 start-page: 104 year: 2010 end-page: 112 ident: bb0035 article-title: Attention deficits in schizophrenia—preliminary evidence of dissociable transient and sustained deficits publication-title: Schizophr. Res. – volume: 30 start-page: 957 year: 2004 end-page: 967 ident: bb0040 article-title: Sleep in untreated patients with schizophrenia: a meta-analysis publication-title: Schizophr. Bull. – volume: 20 start-page: 815 year: 1985 end-page: 816 ident: bb0105 article-title: Sleep-onset REM period in paranoid schizophrenia publication-title: Biol. Psychiatry – volume: 28 start-page: 123 year: 2005 end-page: 144 ident: bb0005 article-title: The clinical use of the MSLT and MWT publication-title: Sleep – volume: 38 start-page: 167 year: 2012 end-page: 177 ident: bb0155 article-title: Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons publication-title: Schizophr Bull. – volume: 20 start-page: 80 year: 2006 end-page: 85 ident: bb0185 article-title: Electroencephalogram slowing, sleepiness and treatment response in patients with schizophrenia during olanzapine treatment publication-title: J. Psychopharmacol. – volume: 8 start-page: 247 year: 1999 end-page: 254 ident: bb0015 article-title: Level of arousal and the ability to maintain wakefulness publication-title: J. Sleep Res. – volume: 166 start-page: 152 year: 2009 end-page: 163 ident: bb0110 article-title: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia publication-title: Am. J. Psychiatry – volume: 113 start-page: 41 year: 2009 end-page: 48 ident: bb0075 article-title: A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study publication-title: Schizophr. Res. – volume: 15 start-page: 73 year: 2005 end-page: 95 ident: bb0050 article-title: A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia publication-title: Neuropsychol. Rev. – volume: 139 start-page: 214 year: 2009 end-page: 219 ident: bb0115 article-title: Sleepiness and vigilance tests publication-title: Swiss Med. Wkly. – volume: 152 start-page: 29 year: 2007 end-page: 35 ident: bb0095 article-title: Sleep onset REM periods in obsessive compulsive disorder publication-title: Psychiatry Res. – year: 1968 ident: bb0150 article-title: A Manual of Standardized Terminology – volume: 123 start-page: 225 year: 2010 end-page: 233 ident: bb0160 article-title: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis publication-title: Schizophr. Res. – volume: 36 start-page: 935 year: 2010 end-page: 948 ident: bb0130 article-title: The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia publication-title: Schizophr. Bull. – volume: 88 start-page: 1183 year: 2008 end-page: 1241 ident: bb0060 article-title: Histamine in the nervous system publication-title: Physiol. Rev. – volume: 164 start-page: 1050 year: 2007 end-page: 1060 ident: bb0120 article-title: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison publication-title: Am. J. Psychiatry – volume: 71 start-page: 127 year: 2004 end-page: 135 ident: bb0045 article-title: Stress and arousability in schizophrenia publication-title: Schizophr. Res. – volume: 45 start-page: 1381 year: 2011 end-page: 1386 ident: bb0180 article-title: Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone publication-title: J. Psychiatr. Res. – volume: 42 start-page: 713 year: 1997 end-page: 720 ident: bb0140 article-title: REM sleep disinhibition at sleep onset: a comparison between narcolepsy and depression publication-title: Biol. Psychiatry – volume: 29 start-page: 687 year: 2006 end-page: 692 ident: bb0055 article-title: The influence of age and sex on sleep latency in the MSLT-30—a normative study publication-title: Sleep – volume: 29 start-page: 890 year: 2006 end-page: 895 ident: bb0170 article-title: The prevalence of multiple sleep-onset REM periods in a population-based sample publication-title: Sleep – volume: 134 start-page: 854 year: 2008 end-page: 861 ident: bb0175 article-title: Multiple sleep latency test and maintenance of wakefulness test publication-title: Chest – volume: 24 start-page: 363 year: 2007 end-page: 365 ident: bb0080 article-title: Minimal impact of inadvertent sleep between naps on the MSLT and MWT publication-title: J. Clin. Neurophysiol. – volume: 117 start-page: 1885 year: 2006 end-page: 1901 ident: bb0135 article-title: Vigilance, alertness, or sustained attention: physiological basis and measurement publication-title: Clin. Neurophysiol. – volume: 164 start-page: 1050 year: 2007 ident: 10.1016/j.schres.2011.12.017_bb0120 article-title: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.164.7.1050 – volume: 20 start-page: 815 year: 1985 ident: 10.1016/j.schres.2011.12.017_bb0105 article-title: Sleep-onset REM period in paranoid schizophrenia publication-title: Biol. Psychiatry doi: 10.1016/0006-3223(85)90167-2 – volume: 42 start-page: 713 year: 1997 ident: 10.1016/j.schres.2011.12.017_bb0140 article-title: REM sleep disinhibition at sleep onset: a comparison between narcolepsy and depression publication-title: Biol. Psychiatry doi: 10.1016/S0006-3223(96)00437-4 – volume: 9 start-page: 5 year: 2000 ident: 10.1016/j.schres.2011.12.017_bb0070 article-title: Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the epworth sleepiness scale: failure of the MSLT as a gold standard publication-title: J. Sleep Res. doi: 10.1046/j.1365-2869.2000.00177.x – volume: 123 start-page: 225 year: 2010 ident: 10.1016/j.schres.2011.12.017_bb0160 article-title: Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis publication-title: Schizophr. Res. doi: 10.1016/j.schres.2010.07.012 – volume: 134 start-page: 854 year: 2008 ident: 10.1016/j.schres.2011.12.017_bb0175 article-title: Multiple sleep latency test and maintenance of wakefulness test publication-title: Chest doi: 10.1378/chest.08-0822 – volume: 29 start-page: 687 year: 2006 ident: 10.1016/j.schres.2011.12.017_bb0055 article-title: The influence of age and sex on sleep latency in the MSLT-30—a normative study publication-title: Sleep doi: 10.1093/sleep/29.5.687 – volume: 129 start-page: 1609 year: 2006 ident: 10.1016/j.schres.2011.12.017_bb0125 article-title: Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults publication-title: Brain doi: 10.1093/brain/awl079 – volume: 28 start-page: 123 year: 2005 ident: 10.1016/j.schres.2011.12.017_bb0005 article-title: The clinical use of the MSLT and MWT publication-title: Sleep doi: 10.1093/sleep/28.1.123 – volume: 36 start-page: 935 year: 2010 ident: 10.1016/j.schres.2011.12.017_bb0130 article-title: The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia publication-title: Schizophr. Bull. doi: 10.1093/schbul/sbq043 – volume: 38 start-page: 167 year: 2012 ident: 10.1016/j.schres.2011.12.017_bb0155 article-title: Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons publication-title: Schizophr Bull. doi: 10.1093/schbul/sbq042 – volume: 160 start-page: 38 year: 2008 ident: 10.1016/j.schres.2011.12.017_bb0010 article-title: Patterns of stress in schizophrenia publication-title: Psychiatry Res. doi: 10.1016/j.psychres.2007.06.001 – volume: 30 start-page: 957 year: 2004 ident: 10.1016/j.schres.2011.12.017_bb0040 article-title: Sleep in untreated patients with schizophrenia: a meta-analysis publication-title: Schizophr. Bull. doi: 10.1093/oxfordjournals.schbul.a007145 – volume: 166 start-page: 152 year: 2009 ident: 10.1016/j.schres.2011.12.017_bb0110 article-title: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.2008.08030368 – volume: 18 start-page: 1411 year: 1983 ident: 10.1016/j.schres.2011.12.017_bb0165 article-title: Sleep onset REM episodes are associated with circadian parameters of body temperature. A study in depressed patients and normal controls publication-title: Biol. Psychiatry – volume: 45 start-page: 1381 year: 2011 ident: 10.1016/j.schres.2011.12.017_bb0180 article-title: Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone publication-title: J. Psychiatr. Res. doi: 10.1016/j.jpsychires.2011.05.009 – volume: 88 start-page: 1183 year: 2008 ident: 10.1016/j.schres.2011.12.017_bb0060 article-title: Histamine in the nervous system publication-title: Physiol. Rev. doi: 10.1152/physrev.00043.2007 – volume: 71 start-page: 127 year: 2004 ident: 10.1016/j.schres.2011.12.017_bb0045 article-title: Stress and arousability in schizophrenia publication-title: Schizophr. Res. doi: 10.1016/j.schres.2004.01.008 – volume: 27 start-page: 662 year: 2007 ident: 10.1016/j.schres.2011.12.017_bb0085 article-title: Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study publication-title: J. Clin. Psychopharmacol. doi: 10.1097/jcp.0b013e31815a8872 – volume: 15 start-page: 73 year: 2005 ident: 10.1016/j.schres.2011.12.017_bb0050 article-title: A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia publication-title: Neuropsychol. Rev. doi: 10.1007/s11065-005-6254-9 – volume: 21 start-page: 579 year: 1995 ident: 10.1016/j.schres.2011.12.017_bb0020 article-title: Clozapine: efficacy and safety publication-title: Schizophr. Bull. doi: 10.1093/schbul/21.4.579 – volume: 9 start-page: 519 year: 1986 ident: 10.1016/j.schres.2011.12.017_bb0030 article-title: Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness publication-title: Sleep doi: 10.1093/sleep/9.4.519 – volume: 113 start-page: 41 year: 2009 ident: 10.1016/j.schres.2011.12.017_bb0075 article-title: A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study publication-title: Schizophr. Res. doi: 10.1016/j.schres.2009.05.024 – year: 1968 ident: 10.1016/j.schres.2011.12.017_bb0150 – volume: 24 start-page: 363 year: 2007 ident: 10.1016/j.schres.2011.12.017_bb0080 article-title: Minimal impact of inadvertent sleep between naps on the MSLT and MWT publication-title: J. Clin. Neurophysiol. doi: 10.1097/WNP.0b013e31811ec488 – volume: 14 start-page: 87 year: 1996 ident: 10.1016/j.schres.2011.12.017_bb0025 article-title: Radioreceptor binding profile of the atypical antipsychotic olanzapine publication-title: Neuropsychopharmacology doi: 10.1016/0893-133X(94)00129-N – volume: 179 start-page: 274 year: 2010 ident: 10.1016/j.schres.2011.12.017_bb0145 article-title: Sleep habits in middle-aged, non-hospitalized men and women with schizophrenia: a comparison with healthy controls publication-title: Psychiatry Res. doi: 10.1016/j.psychres.2009.08.009 – volume: 34 start-page: 118 year: 2009 ident: 10.1016/j.schres.2011.12.017_bb0090 article-title: Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever publication-title: Psychoneuroendocrinology doi: 10.1016/j.psyneuen.2008.08.016 – volume: 29 start-page: 890 year: 2006 ident: 10.1016/j.schres.2011.12.017_bb0170 article-title: The prevalence of multiple sleep-onset REM periods in a population-based sample publication-title: Sleep doi: 10.1093/sleep/29.7.890 – volume: 139 start-page: 214 year: 2009 ident: 10.1016/j.schres.2011.12.017_bb0115 article-title: Sleepiness and vigilance tests publication-title: Swiss Med. Wkly. – volume: 152 start-page: 29 year: 2007 ident: 10.1016/j.schres.2011.12.017_bb0095 article-title: Sleep onset REM periods in obsessive compulsive disorder publication-title: Psychiatry Res. doi: 10.1016/j.psychres.2006.04.003 – volume: 122 start-page: 104 year: 2010 ident: 10.1016/j.schres.2011.12.017_bb0035 article-title: Attention deficits in schizophrenia—preliminary evidence of dissociable transient and sustained deficits publication-title: Schizophr. Res. doi: 10.1016/j.schres.2010.03.019 – volume: 117 start-page: 1885 year: 2006 ident: 10.1016/j.schres.2011.12.017_bb0135 article-title: Vigilance, alertness, or sustained attention: physiological basis and measurement publication-title: Clin. Neurophysiol. doi: 10.1016/j.clinph.2006.01.017 – volume: 8 start-page: 247 year: 1999 ident: 10.1016/j.schres.2011.12.017_bb0015 article-title: Level of arousal and the ability to maintain wakefulness publication-title: J. Sleep Res. doi: 10.1046/j.1365-2869.1999.00168.x – volume: 14 start-page: 540 year: 1991 ident: 10.1016/j.schres.2011.12.017_bb0065 article-title: A new method for measuring daytime sleepiness: the Epworth sleepiness scale publication-title: Sleep doi: 10.1093/sleep/14.6.540 – volume: 38 start-page: 6 year: 2005 ident: 10.1016/j.schres.2011.12.017_bb0100 article-title: A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being publication-title: Pharmacopsychiatry doi: 10.1055/s-2005-837764 – volume: 20 start-page: 80 year: 2006 ident: 10.1016/j.schres.2011.12.017_bb0185 article-title: Electroencephalogram slowing, sleepiness and treatment response in patients with schizophrenia during olanzapine treatment publication-title: J. Psychopharmacol. doi: 10.1177/0269881105056657 |
| SSID | ssj0001507 |
| Score | 2.115344 |
| Snippet | Sleep propensity at daytime has not been investigated in untreated patients with schizophrenia. Furthermore, while the antipsychotics clozapine and olanzapine... Abstract Sleep propensity at daytime has not been investigated in untreated patients with schizophrenia. Furthermore, while the antipsychotics clozapine and... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 123 |
| SubjectTerms | Adolescent Adult Adult and adolescent clinical studies Aged Analysis of Variance Antipsychotic Agents - therapeutic use Atypical antipsychotics Benzodiazepines - therapeutic use Biological and medical sciences Clozapine - therapeutic use Disorders of Excessive Somnolence - drug therapy Disorders of Excessive Somnolence - etiology Double-Blind Method Female Humans Male Medical sciences Middle Aged Neuropharmacology Pharmacology. Drug treatments Polysomnography Psychiatric Status Rating Scales Psychiatry Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychoses Reaction Time - drug effects Schizophrenia Schizophrenia - complications Schizophrenia - drug therapy Sedation Sleep Stages - drug effects Sleepiness Statistics as Topic Time Factors Young Adult |
| Title | Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0920996411006700 https://www.clinicalkey.es/playcontent/1-s2.0-S0920996411006700 https://dx.doi.org/10.1016/j.schres.2011.12.017 https://www.ncbi.nlm.nih.gov/pubmed/22257975 https://www.proquest.com/docview/923577214 |
| Volume | 135 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhvRRKaelr-1h06KE9uOu1ZMk-htCwbbO57AZyE7IesGXxmmhz2B7yL_J_O2PJedCUlIIvsjWWLY1GM9LMN4R8ZLmFRVLrbOoKPGZkJmsKwzJXVkLmRSNND-I6PxGzU_79rDzbI4dDLAy6VSbZH2V6L63TnUnqzUm3Wk0WeY1hn4Ij6BkGm2AEO5fI5V8ub9w8UOHp8fbATMLaQ_hc7-MFBiQYtRHIEzcF-7Rl9y5PTzodoNN8zHbxd3W0X5aOnpGnSZ-kB_GTn5M9174gV4u1cx3tcKO9RacLqrfU6h0mkqc6wIUnvc7SZkfnyaOQRppjjUr0ji6h0UA_zRfHy8901dKEvxoobtzScNtVDx6j6gmvjA_NevNLd6C9Ut1aCqZzG4svyenR1-XhLEv5FzIDdtA2E44L7q3RhtuqkLL0uTCa1Vxg-Kz0ta4b4dFC8r603OZ-KiwrrNagJIjKsldkv9207g2hJq9qzHNcm1xzY4qmqZqclV5CS46VdkTY0O3KJHByzJGxVoMX2k8VB0vhYKlpoWCwRiS7puoiOMcD9cthRNUQeAqiUsHq8QCdvI_OhTTfg5qqADXVHzx5m_IOW_9Dm-M7LHf9g4gZh7hsI0IHHlQgEvCcR7ducxFUjRBGYNnzEXkdefOGGMS3rGX59r-_6x15DKUiuuG9J_vb8wv3AfSybTPuJ96YPDr49mN28ht6aDlq |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCa69LABw7Bhr-zR6bDDdjDi-CHZx6JYka5JLkmB3gRZDyBD4Bhzesj-R_9vSUvOWqxDhwG-2BItWaIpUiI_AnxOY4OLpFLR2CZ0zJjqqEp0Gtm84CJOKqE7ENfZnE8usu-X-eUBnPSxMORWGWS_l-mdtA5PRmE0R81qNVrEJYV98oxAzyjY5BEcEjpVPoDD47PzyXwvkEnn6SD30FIigj6CrnPzQhsS7VqP5Un7gl3msntXqKeNanHcnE948XeNtFuZTp_Ds6BSsmPf6xdwYOuXcL1YW9uwhvbaa_K7YGrLjNpRLnmmWrzosNcaVu3YLDgVMk8zVaRH79gSG23Zl9liuvzKVjULEKwto71b1t721sNi0j7xlb5Qrze_VIMKLFO1YWg91_72FVycflueTKKQgiHSaAptI24znjmjlc5MkQiRu5hrlZYZpwha4UpVVtyRkeRcbjITuzE3aWKUQj2BFyZ9DYN6U9u3wHRclJTquNSxyrROqqqo4jR3AluyaW6GkPbDLnXAJ6c0GWvZO6L9kH6yJE2WHCcSJ2sI0Z6q8fgcD9TP-xmVfewpSkuJC8gDdOI-OtuGX76VY9liTfkHW96mvMPZ_9Dm0R2W238gwcYRNNsQWM-DEqUCHfWo2m6uWlkSihEa99kQ3nje_E2MElyUIn_33_36BI8ny9lUTs_m5-_hCZYk3ivvAwy2P6_sR1TTttVR-A1vABJOPBs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sleep+propensity+at+daytime+as+assessed+by+Multiple+Sleep+Latency+Tests+%28MSLT%29+in+patients+with+schizophrenia+increases+with+clozapine+and+olanzapine&rft.jtitle=Schizophrenia+research&rft.au=Kluge%2C+Michael&rft.au=Himmerich%2C+Hubertus&rft.au=Wehmeier%2C+Peter+M&rft.au=Rummel-Kluge%2C+Christine&rft.date=2012-03-01&rft.eissn=1573-2509&rft.volume=135&rft.issue=1-3&rft.spage=123&rft_id=info:doi/10.1016%2Fj.schres.2011.12.017&rft_id=info%3Apmid%2F22257975&rft.externalDocID=22257975 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09209964%2FS0920996412X00033%2Fcov150h.gif |